Company Performance - Tempus AI reported a quarterly loss of $0.22 per share, slightly better than the Zacks Consensus Estimate of a loss of $0.23, and an improvement from a loss of $0.63 per share a year ago, representing an earnings surprise of +4.35% [1] - The company posted revenues of $314.64 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 5.12%, and showing significant growth from $165.97 million in the same quarter last year [2] - Over the last four quarters, Tempus has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times as well [2] Stock Performance - Tempus shares have increased approximately 74% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.8% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.18 on revenues of $325.52 million, and for the current fiscal year, it is -$0.67 on revenues of $1.24 billion [7] Industry Outlook - The Medical Info Systems industry, to which Tempus belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - The performance of Tempus's stock may be influenced by the overall industry outlook, as empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions [5][8]

Core Viewpoint - Phreesia (PHR) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - An increase in earnings estimates typically leads to higher fair value calculations by institutional investors, resulting in buying or selling pressure that affects stock prices [4]. Company Performance and Outlook - The recent upgrade for Phreesia reflects an improvement in its underlying business, suggesting that investors may respond positively by driving the stock price higher [5]. - For the fiscal year ending January 2026, Phreesia is expected to earn -$0.17 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 41.5% over the past three months [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with only the top 20% receiving a "Strong Buy" or "Buy" rating, indicating superior earnings estimate revisions [9][10]. - Phreesia's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].

Group 1 - TruBridge reported quarterly earnings of $0.36 per share, missing the Zacks Consensus Estimate of $0.37 per share, but showing an increase from $0.19 per share a year ago, resulting in an earnings surprise of -2.70% [1] - The company posted revenues of $87.21 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.51%, and compared to year-ago revenues of $83.25 million [2] - TruBridge has topped consensus revenue estimates four times over the last four quarters, indicating a consistent performance in revenue generation [2] Group 2 - The stock has increased approximately 29.1% since the beginning of the year, contrasting with the S&P 500's decline of -4.7% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is $0.28 on revenues of $87.33 million, and for the current fiscal year, it is $1.79 on revenues of $349.64 million [7] Group 3 - The Medical Info Systems industry, to which TruBridge belongs, is currently in the top 27% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - The Zacks Rank for TruBridge is currently 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6]